# Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

> **NCT03634228** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Milademetan Tosylate
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03634228
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-17
- **Primary completion:** 2022-04-03
- **Final completion:** 2022-04-03
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** This study was terminated early due to lack of adequate response, and did not move to the Phase II portion of the study
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634228, "Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03634228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*